Abstract:Frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17) is a rare inherited neurodegenerative disorder, and most patients with FTDP-17 are caused by mutation of microtubule-associated protein tau (MAPT) gene. Biomarkers study of FTDP-17 showed that temporal lobe hypometabolism appeared prior to clinical symptoms. However, it remains unclear whether dopamine transporter (DAT) distribution, which is potentially related to the parkinsonism in FTDP-17, could predict the onset of disease. In our study, 5 participants including 2 affected patients and 3 asymptomatic mutation carriers were enrolled from a gene-confirmed (N279K mutation) FTDP-17 pedigree from October 2014 and November 2014 for brain metabolism and DAT distribution investigation. Each participant was assessed through standardized clinical evaluation (clinical history, physical examination, MRI, lumbar puncture, etc.), neuropsychology assessment (memory, executive function, speech, naming, etc.), as well as FBI (Frontal Behavioral Inventory, FBI) and UPDRS (Unified Parkinson Disease Rating Scale, UPDARS). Brain metabolism and DAT distribution were estimated by [18F]fludeoxyglucose (FDG) SPECT and [11C]CFT PET, respectively. Clinical, neuropsychology, neuroimaging, and genetic features of 5 participants were listed in Table 1. Parkinsonism was the first symptom for both 2 patients. Personality, speech changes and dementia accompanied with brain atrophy were developed at the later stage in one patient. 3 asymptomatic carriers showed no clinical, neuropsychology or structural imaging abnormality. (2) The [18F]FDG SPECT studies illustrated asymmetric hypometabolism of the temporal lobes in 5 participants. In addition, hypometabolism of the frontal lobes and parietal lobes were seen in 2 affected patients and 2 mutation carriers, and basal ganglia changes were observed in 2 affected patients. (3) Regarding to the [11C]CFT PET, all the 4 examined participants (2 affected patients and 2 mutation carriers) showed asymmetric decreased uptake of tracer in basal ganglia regions (Figure 2). Pedigree of the FTDP-17 family with MAPT N279K mutation Brain metabolism of an affected participant (A) and an at-risk asymptomatic mutation carrier (B) DAT distribution at basal ganglia of an affected participant (A) and an at-risk asymptomatic mutation carrier (B) The feature of brain hypometabolism and decreased DAT can predict the disease at least 15 years before the onset of the elder generation of patients, and 7 years before the onset of peer of patients. Therefore, brain metabolism and DAT distribution could be a potential biomarker in early diagnosis of FTDP-17, even at the asymptomatic stage.

Neuroimaging and Neuropsychological Findings in MAPT N279K Mutation Phenoconverters

ACCELERATED NEUROCHEMICAL CHANGES PRIOR TO PHENOCONVERSION TO FRONTOTEMPORAL LOBAR DEGENERATION IN PRESYMPTOMATIC MICROTUBULE-ASSOCIATED PROTEIN TAU (MAPT) MUTATION CARRIERS: A LONGITUDINAL MRS STUDY

Brain volumetric deficits in MAPT mutation carriers: a multisite study

Mr spectroscopy from frontal lobe and posterior cingulate gyrus in asymptomatic and symptomatic microtubule-associated protein tau (mapt) mutation carriers

Neurite-based white matter alterations in MAPT mutation carriers: A multi-shell diffusion MRI study in the ALLFTD consortium

Rates of Lobar Atrophy in Asymptomatic MAPT Mutation Carriers

P2-329: TRACKING WHITE MATTER DEGENERATION IN ASYMPTOMATIC AND SYMPTOMATIC MAPT MUTATION CARRIERS WITH DTI

Clinical and Pathological Features of FTDP-17 with MAPT p.K298_H299insQ Mutation

Clinical and neuroimaging characterization of the first frontotemporal dementia family carrying the MAPT p.K298E mutation

P3‐148: Brain Hypometabolism and Decreased Dopamine Transporter Distribution in Asymptomatic MAPT N279K Mutation Carriers in Familial FTDP‐17 Pedigree from China

MAPT Mutations V337M and N297K Alter Organelle Trafficking in Frontotemporal Dementia Patient-Specific Motor Neurons

Imaging Biomarkers for Neurodegeneration in Presymptomatic Familial Frontotemporal Lobar Degeneration

In Vivo 18 F‐APN ‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

In Vivo18F‐APN‐1607 Tau Positron Emission Tomography Imaging in MAPT Mutations: Cross‐Sectional and Longitudinal Findings

Longitudinal cognitive biomarkers predicting symptom onset in presymptomatic frontotemporal dementia

Synaptic gene expression changes in frontotemporal dementia due to the MAPT 10 + 16 mutation

Longitudinal Magnetic Resonance Imaging in Asymptomatic C9orf72 Mutation Carriers Distinguishes Phenoconverters to Amyotrophic Lateral Sclerosis or Amyotrophic Lateral Sclerosis With Frontotemporal Dementia

Tracking White Matter Degeneration in Asymptomatic and Symptomatic MAPT Mutation Carriers.

Longitudinal cerebral perfusion in presymptomatic genetic frontotemporal dementia: GENFI results

The MAPT p.E342K and p.R406W mutations are associated with progressive supranuclear palsy with atypical features

Q351R MAPT mutation is associated with a mixed 3R/4R tauopathy and a slowly progressive cognitive, behavioural and parkinsonian syndrome